Neural Differentiation of Human Umbilical Cord Mesenchymal Stem Cells by Cerebrospinal Fluid
How to Cite This Article: : Farivar S, Mohamadzade Z, Shiari R, Fahimzad AR. Neural Differentiation of Human Umbilical Cord
Mesenchymal Stem Cells by Cerebrospinal Fluid. . Iran J Child Neurol. 2015 Winter; 9(1):87-93.
Wharton’s jelly (WJ) is the gelatinous connective tissue from the umbilical cord. It is composed of mesenchymal stem cells, collagen fibers, and proteoglycans. The stem cells in WJ have properties that are interesting for research. For example, they are simple to harvest by noninvasive methods, provide large numbers of cells without risk to the donor, the stem cell population may be expanded in vitro, cryogenically stored, thawed, genetically manipulated, and differentiated in vitro. In our study, we investigated the effect of human cerebrospinal fluid (CSF) on neural differentiation of human WJ stem cells.
Material & Methods
The cells in passage 2 were induced into neural differentiation with different concentrations of human cerebrospinal fluid. Differentiation along with neural lineage was documented by expression of three neural markers: Nestin, Microtubule-Associated Protein 2 (MAP2), and Glial Fibrillary Astrocytic Protein (GFAP) for 21 days. The expression of the identified genes was confirmed by Reverse Transcriptase PCR (RT-PCR).
Treatment with 100 and 200μg/ml CSF resulted in the expression of GFAP and glial cells marker on days 14 and 21. The expression of neural-specific genes following CSF treatment was dose-dependent and time-dependent. Treatment of the cells with a twofold concentration of CSF, led to the expression of MAP2 on day 14 of induction. No expression of GFAP was detected before day 14 or MAP2 before day 21, which shows the importance of the treatment period. In the present study, expression analysis for the known neural markers: Nestin, GFAP, and MAP2 using RT-PCR were performed. The data demonstrated that CSF could play a role as a strong inducer.
RT-PCR showed that cerebrospinal fluid promotes the expression of Nestin, MAP2, and GFAP mRNA in a dose-dependent manner, especially at a concentration of 200 μl/ml. In summary, CSF induces neurogenesis of WJ stem cells that encourages tissue engineering applications with these cells for treatments of neurodegenerative defects and traumatic brain injury.
- Gage, F. H. Mammalian neural stem cells. Science 2000 Feb 25;287(5457):1433-8.
- Da Silva Meirelles L, Chagastelles PC, Nardi NB. Mesenchymal stem cells reside in virtually all postnatal organs and tissues. J Cell Sci 2006 Jun 1;119(Pt 11):2204- 13. Epub 2006 May 9.
- Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR. Multilineage potential of adult human mesenchymal stem cells Science 1999 Apr 2;284(5411):143-7.
- Tse WT, Pendleton JD, Beyer WM, Egalka MC, Guinan EC. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation 2003 Feb 15;75(3):389- 97.
- Le Blanc K. Immuno-modulatory effects of fetal and adult mesenchymal stem cells. Cytotherapy 2003;5(6):485-9.
- Stenderup K, Justesen J, Clausen C, Kassem M. Aging is associated with decreased maximal life span and accelerated senescence of bone marrow stromal cells. Bone 2003 Dec;33(6):919-26.
- Bongso A, Fong CY, Gauthaman K. Taking stem cells to the clinic: major challenges. J Cell Biochem 2008 Dec 15;105(6):1352-60. doi: 10.1002/jcb.21957.
- Fong CY, Chak LL, Biswas A. Human Wharton’s jelly stem cells have unique transcriptome profiles compared to human embryonic stem cells and other mesenchymal stem cells. Stem Cell Rev 2011 Mar;7(1):1-16. doi: 10.1007/s12015-010-9166-x.
- Troyer DL, Weiss ML. Wharton’s jelly-derived cells are a primitive stromal cell population. Stem Cells 2008 Mar; 26(3):591-9. Epub 2007 Dec 6.
- Yuan X, Desiderio DM. Proteomics analysis of human cerebrospinal fluid. J Chromatogr B Analyt Technol Biomed Life Sci 2005 Feb 5;815(1-2):179-89.
- Thompson, EJ. Cerebrospinal fluid. J Neurol Neurosurg Psychiatry 1995 Oct;59(4):349-57.
- Alcazar A, Regidor I, Masjuan J, Salinas M, Alvarez- Cermeno JC. Induction of apoptosis by cerebrospinal fluid from patients with primary-progressive multiple sclerosis in cultured neurons. Neurosci Lett 1998 Oct 16;255(2):75-8.
- Colombo JA, Napp MI. Cerebrospinal fluid from L-dopa-treated Parkinson’s disease patients is dystrophic for various neural cell types exvivo: effects of astroglia. Exp Neurol 1998 Dec;154(2):452-63.
- Redzic ZB, Preston JE, Duncan JA, Chodobski A, Szmydynger-Chodobska J. The choroid plexus-cerebrospinal fluid system: from development to aging. Current topics in developmental biology 2005; (71): 1-52.
- Bachy I, Kozyraki R, Wassef M. The particles of the embryonic cerebrospinal fluid: how could they influence brain development? Brain Res Bull 2008 Mar 18;75(2- 4):289-94. doi: 10.1016/j.brainresbull.2007.10.010.
- Parada C, Gato A, Bueno D. Mammalian embryonic cerebrospinal fluid proteome has greater apo-lipoprotein and enzyme pattern complexity than the avian proteome. Journal of proteome research 2005; 4(6): 2420- 2428.
- Martin C, Bueno D, Alonso MI, Moro JA, Callejo S, Parada C, Martin P, Carnicero E, Gato A. FGF2 plays a key role in embryonic cerebrospinal fluid trophic properties over chick embryo neuro epithelial stem cells. Dev Biol 2006 Sep 15;297(2):402-16. Epub 2006 May 19.
- Huttner HB, Janich P, Kohrmann M, Jaszai J, Siebzehnrubl F, Blumcke I, Suttorp M, Gahr M, Kuhnt D, Nimsky C. The stem cell markerprominin-1/CD133 on membrane particles in human cerebrospinal fluid offers novel approaches for studying central nervous system disease. Stem Cells 2008 Mar;26(3):698-705.
- Nordin C, Gupta RC, Sjodin I. Cerebrospinal fluid amino acids in pathological gamblers and healthy controls. Neuropsychobiology 2007;56(2-3):152-8. doi: 10.1159/000115782. Epub 2008 Feb 7.
- Gato A, Martin P, Alonso MI, Martin C, Pulgar MA, Moro JA. Analysis of cerebro-spinal fluid protein composition in early developmental stages in chick embryos. J Exp Zool A Comp Exp Biol 2004 Apr 1;301(4):280-9.
- Mitchell KE, Weiss ML. Matrix cells from Wharton’s jelly form neurons and glia. Stem Cells 2003;21(1):50-60.
- Marcus AJ, Woodbury D. Fetal stem cells from extra-embryonic tissues: do not discard. J Cell Mol Med 2008 Jun;12(3):730-42. doi: 10.1111/j.1582- 4934.2008.00221.x. Epub 2008 Jan 11.
- Miao Z, Jin J, Chen L, Zhu J, Huang W, Zhao J, Quian H, Zhang X. Isolation of mesenchymal stem cells from human placenta: comparison with human bone marrow mesenchymal stem cells. Cell Biol Int 2006 Sep;30(9):681-7. Epub 2006 Apr 22.
- In ‘tAnker PS, Scherjon SA, Kleijburg-van der Keur C, Noort WA, Claas FHJ, Willemze R, Fibbe WE, Kanhai HHH. Amniotic fluid as a novel source of mesenchymal stem cells for therapeutic transplantation. Blood 2003;102(4):1548-49.
- Magatti M, De Munari S, Vertua E, Gibelli L, Wengler GS, Parolini O. Human amnion mesenchyme harbors cells with allogeneic T-cell suppression and stimulation capabilities. Stem Cells 2008 Jan;26(1):182-92. Epub 2007 Sep 27.
- Kang XQ, Zang WJ, Bao LJ, Li DL, Xu XL, Yu XJ. Differentiating characterization of human umbilical cord blood-derived mesenchymal stem cells in vitro. Cell Biol Int 2006 Jul;30(7):569-75. Epub 2006 Mar 6.
- Kern S, Eichler H, Stoeve J, Kluter H, Bieback K. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells 2006 May;24(5):1294-301. Epub 2006 Jan 12.
- Wagner W, Wein F, Seckinger A, Frankhauser M, Wirkner U, Krause U, et al. Comparative characteristics of mesenchymal stem cells from human bone marrow, adipose tissue, and umbilical cord blood. Exp Hematol 2005 Nov;33(11):1402-16.
- Jackson JS, Golding JP, Chapon C, Jones WA, Bhakoo KK: Homing of stem cells to sites of inflammatory brain injury after intracerebral and intravenous administration: a longitudinal imaging study. Stem Cell Res Ther 2010 Jun 15;1(2):17. doi: 10.1186/scrt17.
- Romanov YA, Svintsitskaya VA, Smirnov VN. Searching for alternative sources of postnatal human mesenchymal stem cells: candidate MSC-like cells from umbilical cord. Stem Cells 2003;21(1):105-10.
- Weiss ML, Medicetty S, Bledsoe AR. Human umbilical cord matrix stem cells: Preliminary characterization and effect of transplantation in a rodent model of Parkinson’s disease. Stem Cells 2006 Mar;24(3):781-92.
- Carlin R, Davis D, Weiss M. Expression of early transcription factors Oct4, Sox2 and Nanog by porcine umbilical cord (PUC) matrix cells. Reprod Biol Endocrinol. 2006 Feb;6(4):8.
- Usha Nekanti, Sumitava Dastidar, Parvathy Venugopal, Satish Totey and Malancha Ta. Increased Proliferation and Analysis of Differential Gene Expression in Human Wharton’s Jelly-derived Mesenchymal Stromal Cells under Hypoxia. Int J Biol Sci. 2010; 6(5): 499–512.
The entire contents of the Iranian Journal of Child Neurology are protected under international copyrights. This journal is for your personal noncommercial use. You may not modify, copy, distribute, transmit, display, or publish any materials contained on the Journal without the prior written permission of it or appropriate copyright owne.
Copy Right Letter of (Iran J Child Neurol)
Pls find attached a copy of the subject copyright work and assigned it:
To: Iranian Journal of Child Neurology
The Editor: Prof. Parvaneh Karimzadeh, Editor in Chief of IJCN
We intend to publish entitle “ ……………………………………………………………………” in your journal as an Original Article/ Case Report/Systematic Review/Review Article/ Neurometabolic Disorder Article/ Letter to Editor.
ON behalf of all the contributors Q will act and guarantor and will correspond with the journal from this point onward.
Conflict of interest
We hereby transfer, assign, or otherwise convey all copyright ownership, including any and all rights incidental thereto, exclusively to the journal, in the event that such work is published by the journal.
We would like to suggest following referee for the article.
I am corresponding author of the work and my contact details are found in the block above.
I/We certify that I/we have participated sufficiently in the intellectual content, conception and design of this work or the analysis and interpretation of the data (when applicable), as well as the writing of the manuscript, to take public responsibility for it and have agreed to have my/ our name listed as contributor. I /we believe the manuscript represents valid work. Neither this manuscript nor one with substantially similar content under my/our authorship has seem published or is being considered for publication elsewhere, except as described in the covering letter. I /we certify that all the data collected during the study is presented in this manuscript and no data from the study has been or will be published separately. I/we attest that, if requested by the editors, I /we will provide the data/information or will cooperate fully in obtaining and providing the data/ information on which the manuscript is based, foe examination by the editors of their assignees. Financial interests, direct or indirect, that exist or may be perceived to exist for individual contributors in connection with the content of this paper have been disclosed in the cover letter. Sources of outside support of the project are named in the cover letter.
I/We hereby transfer)s), assign(s) or otherwise convey(s) all copyright ownership, including any and all right incidental thereto, exclusively to the Journal, in the event that such work is published by the Journal. The Journal shall own the work, including 1) copyright; 2) the right to grant permission to republish the article in whole or in print, with or without fee; 3) the right to produce preprints or reprints and translate into languages other than English for sale or free distribution, and; 4) the right to republish the work in a collection of articles in ant other mechanical or electronic format.
We give the right to the corresponding author to make necessary changes as per the request of the journal, do the rest of the correspondence on our behalf and he/she will act as the guarantor for the manuscript on our behalf.
All persons who have made substantial contributions to the work reported in the manuscript, but who are not contributors, are named in the Acknowledgement and have given me /us their written permission to be names. If I/we do not include Acknowledgment that means I/we have not received substantial contributions from the non-contributors and no contributor has been omitted.
Name Signature date signed
1………………………. ………………. ………….
2.………………………. ………………. ………….
3.………………………. ………………. ………….
4.………………………. ………………. ………….
5.………………………. ………………. ………….